Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab plus cobimetinib plus eribulin in patients with metastatic inflammatory breast cancer

CANCER RESEARCH(2023)

引用 0|浏览20
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要